On May 19, 2026 Torqur AG, a subsidiary of Swiss Rockets AG, reported it will present new clinical and translational findings from its actinic keratosis (AK) program at the 7th Dermatology Drug Development Summit Europe, taking place in Amsterdam, the Netherlands, from May 19–21, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the summit, the Torqur team will deliver a scientific presentation, highlighting the company’s progress in the development of topical bimiralisib for actinic keratosis (AK), a common precancerous skin condition with significant unmet medical need.
The presentation will feature recent clinical and translational data supporting the continued development of bimiralisib, a dual pan PI3K/mTOR inhibitor designed to target a key oncogenic signaling pathway involved in the progression of actinic keratosis and cutaneous squamous cell carcinoma. Recent clinical findings demonstrated encouraging field-directed efficacy and favorable tolerability, supporting a differentiated mechanism-driven therapeutic approach.
Alongside the topical bimiralisib program, the oral bimiralisib program is informed by the broader oncology interest in targeting the PI3K/mTOR pathway, one of the most frequently dysregulated pathways in cancer. While many approaches have focused on isoform-selective inhibition, increasing scientific attention is being given to broader pathway inhibition to address pathway complexity and resistance mechanisms, positioning bimiralisib as a differentiated dual PI3K/mTOR inhibitory approach.
Torqur AG will be represented at the summit by Dr. Dana Novac, Chief Medical Officer; Dr. Petra Hillmann, Head of Translational Science; and Dr. Patrick Schnider, Head of Research & Development.
Dana Novac and Petra Hillmann will represent the company as featured speakers during the scientific program.
"Actinic keratosis remains a disease in which patients and physicians continue to need more effective and better-tolerated treatment options. We look forward to presenting the progress of our bimiralisib program and discussing the translational and clinical findings supporting its further development," said Dana Novac, Chief Medical Officer.
(Press release, Torqur, MAY 19, 2026, View Source [SID1234665870])